Research Reference
Goserelin
FDA-approved injectable GnRH superagonist for hormone-sensitive cancers
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Goserelin (Zoladex) is an FDA-approved injectable GnRH superagonist for hormone-sensitive cancers.
Dosing Reference
Reconstitution
Add 1 mL bacteriostatic water to the 3.6 mg vial. Resulting concentration: 3.6 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 3.6 mg | 100 units | 1 mL | SubQ, monthlyMonthly depot (FDA) |
| 10.8 mg | 300 units | 3 mL | SubQ, every 3 months3-month depot (FDA) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Goserelin (Zoladex) is FDA-approved for prostate cancer, breast cancer, and endometriosis, supplied as a pre-filled depot implant administered subcutaneously (1-month or 3-month). It is not user-reconstituted from lyophilized powder. Compounded research-peptide forms are not FDA-approved.
For compounded forms, concentration depends on vial size and diluent volume; no standard compounded protocol exists. Compounded forms are not FDA-approved.
Cycling Protocol
FDA-approved goserelin is used as chronic depot therapy (monthly or every 3 months) for the indicated condition; no fixed cycle end. Dosing frequency depends on the specific depot formulation prescribed.
Routes of Administration
Subcutaneous depot implant (only established route): Administered as a pre-filled depot implant into the abdominal subcutaneous tissue every 1 or 3 months, in a clinical setting.
No oral route is established (peptide). Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Androgen deprivation | Goserelin + antiandrogen | Standard prostate cancer protocol (FDA, under oncology supervision) | | Breast cancer | Goserelin + endocrine therapy | Hormone-receptor-positive breast cancer protocol (FDA) |
Goserelin combinations are managed under specialist oncology supervision. Compounded forms are not FDA-approved.
Side Effects & Safety
- Hot flashes — very common
- Decreased libido, sexual dysfunction — common
- Bone density loss — risk with long-term use
- Injection-site reactions / bruising — common
- Mood changes, depression — common
- Tumor flare — transient hormone increase at initiation
- Cardiovascular events — risk, especially in prostate cancer use
Goserelin (Zoladex) is FDA-approved for prostate cancer, breast cancer, and endometriosis. Compounded research-peptide forms are not FDA-approved.
Research Basis
Goserelin is a synthetic GnRH (gonadotropin-releasing hormone) agonist, FDA-approved (Zoladex).
Mechanism: Initially stimulates then suppresses gonadotropin (LH/FSH) release via pituitary GnRH receptor downregulation, leading to suppressed testosterone (men) or estrogen (women) — chemical castration.
Clinical evidence: FDA-approved for prostate cancer (androgen deprivation), hormone-receptor-positive breast cancer, and endometriosis. Extensive clinical experience.
FDA-approved for the indications above. Compounded research-peptide forms are not FDA-approved.